AbbVie agreed on 22 June to acquire Apogee Therapeutics for $135.11 a share in cash, valuing the clinical-stage immunology company at about $10.9bn.
Why AbbVie Inc. is buying Apogee Therapeutics, Inc.
AbbVie said the deal deepens its immunology franchise and accelerates its move into respiratory disease. In a phase 2 trial about two-thirds of atopic dermatitis patients on zumilokibart achieved significant skin clearance at 16 weeks, and longer-term data supported quarterly or twice-yearly maintenance dosing.
“The acquisition of Apogee further builds on our existing leadership, strengthening our ability to deliver innovative medicines to patients who need better options while also creating significant long-term value for shareholders.”
Deal terms and financing
The all-cash deal was unanimously approved by both boards and required Apogee shareholder approval. AbbVie expected it to be accretive to adjusted diluted EPS from 2032; at completion it guided to dilution of $0.14 in 2026 and about $0.46 in 2027.
Regulatory approvals and timing
Closing required regulatory approvals and was expected in the third quarter. Apogee's shares ceased trading on Nasdaq before the open on 3 September 2026, when AbbVie completed the deal.
Market context
The deal was one of two biopharma takeovers above bn announced in June, alongside GSK's purchase of Nuvalent. Apogee is based in San Francisco and Boston.
